Division of Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, and Chung Shan Medical University, Taichung, Taiwan.
Ann Surg Oncol. 2012 Jul;19(7):2149-58. doi: 10.1245/s10434-012-2273-y. Epub 2012 Mar 10.
To investigate the impact of endoscopic esophageal tumor length on survival for patients with resected esophageal squamous cell carcinoma (ESCC).
We retrospectively reviewed the clinicopathologic characteristics of 244 ESCC patients who underwent curative resection as the primary treatment at Taipei Veterans General Hospital between January 2000 and November 2010. The endoscopic tumor length was defined as a uniform measurement before completion of the esophagectomy. The impact of endoscopic tumor length on a patient's overall survival (OS) and disease-free survival (DFS) were assessed. A Cox regression model was used to identify prognostic factors.
The 1-, 3-, and 5-year OS rates were 81.2, 48.2, and 39.6%, respectively, with a median survival time of 18.0 months. The 1-, 3-, and 5-year DFS rates were 66.2, 34.7, and 32.4%, respectively, with a median DFS of 15.0 months. Endoscopic tumor length correlated with pathologic tumor length [Pearson correction (r)=0.621; P<0.001] Regression trees analyses suggested an optimum cutoff point of >4 cm to identify patients with decreased long-term survival. In multivariate survival analysis, endoscopic tumor length (more or less than 4 cm) remained an independent prognostic factor for both OS (P=0.006) and DFS (P=0.002).
Endoscopic tumor length could have a significant impact on both the OS and DFS of patients with resected ESCC and may provide additional prognostic value to the current tumor, node, and metastasis staging system before patients receive any cancer-specific treatment.
研究内镜下食管肿瘤长度对可切除食管鳞癌(ESCC)患者生存的影响。
我们回顾性分析了 2000 年 1 月至 2010 年 11 月在台北荣民总医院接受根治性切除术的 244 例 ESCC 患者的临床病理特征。内镜下肿瘤长度定义为完成食管切除术前的统一测量值。评估内镜下肿瘤长度对患者总生存(OS)和无病生存(DFS)的影响。采用 Cox 回归模型确定预后因素。
1、3、5 年 OS 率分别为 81.2%、48.2%和 39.6%,中位生存时间为 18.0 个月。1、3、5 年 DFS 率分别为 66.2%、34.7%和 32.4%,中位 DFS 为 15.0 个月。内镜下肿瘤长度与病理肿瘤长度相关(Pearson 校正 r=0.621;P<0.001)。回归树分析表明,>4cm 是识别长期生存降低的最佳截断点。多变量生存分析显示,内镜下肿瘤长度(>4cm 或<4cm)仍然是 OS(P=0.006)和 DFS(P=0.002)的独立预后因素。
内镜下肿瘤长度对可切除 ESCC 患者的 OS 和 DFS 有显著影响,并且在患者接受任何特定于癌症的治疗之前,可能为当前的肿瘤、淋巴结和转移分期系统提供额外的预后价值。